Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

10.30 +0.23 (+2.28%)

Streaming Delayed Price Updated: 2:40 PM EST, Dec 4, 2025 Add to My Watchlist

Price and Volume

Volume	47,262
Open	9.940
Bid (Size)	10.20 (200)
Ask (Size)	10.28 (900)
Prev. Close	10.07
Today's Range	9.520 - 10.33
52wk Range	4.930 - 21.79
Shares Outstanding	33,197,018
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

What One Fund's Sale of Centessa Stock Signals About the Fast-Rising Biotech Company ↗

November 29, 2025

Here's why a fast-rising pharmaceutical trimmed—and not abandoned—by a specialist fund signals ongoing conviction in the stock.

Via The Motley Fool

5AM Venture Just Dumped Its Viking Stake—Smart Call or Missed Opportunity? ↗

November 18, 2025

One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the company’s clinical-stage future.

Via The Motley Fool

Performance

YTD	-41.0%	-41.0%
1 Month	+51.9%	+51.9%
3 Month	+93.6%	+93.6%
6 Month	+29.9%	+29.9%
1 Year	-48.9%	-48.9%

More News

5AM Venture Bails on MoonLake After a Brutal Year: Here’s What Stands Out ↗

November 18, 2025

Via The Motley Fool

Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock ↗

November 06, 2024

Via Benzinga

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

November 06, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics to Present at Upcoming Investor Conferences

October 28, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

September 05, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 02, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada (TRDA) Q2 Revenue Drops 98% ↗

August 06, 2025

Via The Motley Fool

Entrada Therapeutics Inc (NASDAQ:TRDA) Reports Q2 2025 Earnings Miss, Shares Drop in Pre-Market Trading ↗

August 06, 2025

Via Chartmill

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

August 06, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 03, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 02, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 08, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

March 24, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

February 27, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy ↗

February 24, 2025

Via Benzinga

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

February 24, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

February 03, 2025

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 18, 2024

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

November 05, 2024

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

October 09, 2024

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

September 24, 2024

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

September 06, 2024

From Entrada Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Entrada Therapeutics, Inc. - Common Stock publicly traded?

Yes, Entrada Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Entrada Therapeutics, Inc. - Common Stock trade on?

Entrada Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Entrada Therapeutics, Inc. - Common Stock?

The ticker symbol for Entrada Therapeutics, Inc. - Common Stock is TRDA on the Nasdaq Stock Market

What is the current price of Entrada Therapeutics, Inc. - Common Stock?

The current price of Entrada Therapeutics, Inc. - Common Stock is 10.30

When was Entrada Therapeutics, Inc. - Common Stock last traded?

The last trade of Entrada Therapeutics, Inc. - Common Stock was at 12/04/25 02:40 PM ET

What is the market capitalization of Entrada Therapeutics, Inc. - Common Stock?

The market capitalization of Entrada Therapeutics, Inc. - Common Stock is 341.93M

How many shares of Entrada Therapeutics, Inc. - Common Stock are outstanding?

Entrada Therapeutics, Inc. - Common Stock has 342M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.